BEIJING (Reuters) – About 90% of China's Sinovac Biotech Ltd employees and their families have received an experimental coronavirus vaccine developed by the pharmaceutical company itself, the CEO said Sunday.
The scale of the emergency vaccine program that China began in July shows how actively China is using experimental vaccines in hopes of vital workers against a potential resurgence of the COVID-19 surge, even though trials are still pending.
The program is targeted at specific groups, including healthcare professionals and those working in the food markets, as well as in the transport and services sectors.
Sinovac, whose CoronaVac vaccine is in its third phase of clinical trials and has been included in an emergency program, has offered the potential vaccine to approximately 2,000 to 3,000 employees and their families on a voluntary basis, the company's CEO said.
(Roxanne Liu and Tony Munroe. Translated by Olga Vishnevskaya. Editor Anna Kozlova)